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Carboxypeptidase O (CPO) is a membrane-bound peptidase that cleaves acidic and polar 
C-terminal amino acids of peptides; however, its biological function remains unknown. CPO is 
strongly expressed in the small intestine, where it has been proposed to participate in digestion 
events at the brush border by extracellular cleavage of dietary peptides. At the subcellular level, 
CPO is anchored to the inner leaflet of the endoplasmic reticulum (ER) membrane, where it has 
been shown to associate with lipid droplets (LDs). The ER membrane also represents the site of 
iv 
chylomicron formation, a process that shares many similarities with that of LDs biogenesis. We 
sought to investigate a potential role of CPO in LD and chylomicron formation. Using a stably-
expressing human colon carcinoma (Caco-2) cell model, we evaluated CPO association with 
LDs and apoB, a chylomicron biomarker, by immunofluorescence microscopy. The association 
of CPO with LDs was dependent on the time elapsed post-feeding (ANOVA, p < 0.05), and was 
lowest at 6 h (17.9%), reaching a maximum at 12 h (29.8%) and later slightly decreasing at 24 h 
(26.3%). Our results indicate that CPO associated with apoB, further showing a similar 
association pattern as that of LDs at the three time points. However, we express a limited level of 
confidence in these results since the immunocytochemistry images presumably suggest lower 
association levels than those reported in the quantification data. Overall, our findings strengthen 
the hypothesis that CPO plays an intracellular role in the formation of lipid droplets in 
enterocytes. 
To better understand the potential biological role of CPO, we performed an in-depth 
analysis of data from several gene expression databases and platforms. RNA-Seq and microarray 
expression data showed high expression in the ileum epithelium and mucosa. Modulation of 
CPO expression, which was mainly characterized by downregulation in the ileum, was found in 
ulcerative colitis and Crohn’s disease, with the latter showing stronger modulation. RNA-Seq 
data also showed prominent expression in Peyer’s patches and basophils, which suggested a 
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1. Carboxypeptidases  
Carboxypeptidases are enzymes characterized for cleaving the C-terminal amino acid of 
peptides and proteins and are known to have diverse physiological functions such as cell 
signaling and digestion (Fricker, 2011). Carboxypeptidases are grouped in two major categories: 
serine carboxypeptidases, which contain a serine residue at the active site, and 
metallocarboxypeptidases, which contain a zinc atom. The M14 is an important family of 
metallocarboxypeptidases with unique physiological functions in humans (Fig. 1). Substrate 
specificity exists within the members of this family, with some members exhibiting preference 
for basic residues (i.e. CPB2, CPE), acidic residues (i.e. CPO), or non-polar aliphatic/aromatic 















Figure 1. Phylogeny of the M14 metallocarboxypeptidase family. In red, CPE, CPB2, and CPO. 
Contrary to CPO, CPE and CPB2 are well-characterized carboxypeptidases with important 
physiological functions such as neuropeptide processing and proteolytic cleavage.  
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A number of studies have successfully described the physiological functions of several 
M14 carboxypeptidases. For example, studies by Ji et al. (2017) and Chen et al. (2001) identified 
the role of carboxypeptidase E (CPE) in the synthesis of neuropeptides and peptide hormones, 
vesicular transport, cellular signaling, and neuroprotection. CPE was originally named 
enkephalin convertase after it was found to proteolytically cleave the C-terminal basic amino 
acid residues of enkephalin precursors within adrenal chromaffin granules of cattle (Fricker and 
Snyder, 1982). In a subsequent study in rats, CPE was found to participate in conjunction with 
endoproteases in mid stages of development in rats, where they processed neuropeptide 
precursors in the brain as well as proproteins in multiple peripheral locations (Zheng et al., 
1994). Due to its supporting role in proinsulin processing (Harding and Ron, 2002), mutations in 
the CPE gene have been directly associated with development of type 2 diabetes in mice and 
humans (Fricker et al., 1996; Harding and Ron, 2002). In addition, CPE has been reported to 
provide neuronal protection against oxidative stress and cell death (Cong et al., 2017). Moreover, 
CPE participates in anterograde transport of synaptic vesicles, which allows for their recycling or 
degradation (Ji et al., 2017).  
Another M14 member with a significant biological role is thrombin-activatable 
procarboxypeptidase B (proCPB2) also known as thrombin-activatable fibrinolysis inhibitor 
(TAFI). Following activation by proteolytic cleavage, CPB2 mediates several physiological 
functions, namely fibrinolysis, coagulation, and inflammation (Novakovic et al., 2012). Its 
inhibitory role in the fibrinolysis cascade is executed through cleavage of the C-terminal lysine 
residues from partially degraded fibrin, hence preventing further fibrin degradation by other 
enzymes (Leung et al., 2008; Novakovic et al., 2012). In addition, CPB2 is said to work in 
conjunction with protein C during injury response at the vascular epithelium: protein C reduces 
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the clotting while CPB2 protects the fibrin clot from premature lysis (Leung et al., 2008). A 
potential role of CPB2 in inflammation has been proposed after observation of proteolysis of 
proinflammatory mediators such as bradykinin, complement C3a and C5a, and thrombin‐cleaved 
osteopontin (Novakovic et al., 2012).  
Overall, a large number of physiological functions of carboxypeptidases (i.e. CPB2 and 
CPE) have been described to date. While some studies continue to further investigate well-
characterized members of the M14 family, a new interest has emerged to investigate less-known 
members. Thus, Lyons and Fricker (2011) recently identified carboxypeptidase O (CPO), a 
previously uncharacterized member of the M14 family and closely related to CPB2 (Fig. 1). CPO 
was described as a fully functional peptidase that cleaves acidic and polar C-terminal amino 
acids of peptides (Burke et al., 2018; Lyons and Fricker, 2011). In addition, CPO was shown to 
be expressed on the small intestine, more specifically on the apical surface of enterocytes, and 
anchored to the membrane through a glycosylphosphatidylinositol (GPI) modification (Lyons 
and Fricker, 2011). Taken together, these findings allude to CPO working extracellularly, likely 
cleaving dietary peptides in the intestine (Garcia-Guerrero et al., 2018). Overall, there is a high 
possibility of CPO working extracellularly given that 1) GPI anchored proteins are almost 
exclusively present on the outer leaflet of the plasma membrane and 2) its location on the apical 
surface coincides with that of most GPI-anchored proteins in polarized epithelial cells (Zurzolo 
and Simons, 2016).  
In addition to the proposed extracellular function cleaving dietary peptides, CPO might 
also play an intracellular role. This possibility was suggested after observation of intracellular 
expression of CPO in canine-derived epithelial cells where CPO was GPI-anchored to the inner 
leaflet of the ER membrane and associated with LDs within this compartment (Burke et al., 
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2018). Overexpression of CPO led to an increase in the number of LDs, as determined by 
immunofluorescence microscopy. This finding suggested a physiological function of CPO in the 
biogenesis of lipid droplets.  
Burke et al. (2018) further hypothesized that CPO could play a role in the formation of  
chylomicrons. This suggestion was based on the many similarities between their formation 
processes. The most accepted model states that their formation begin due to an accumulation of 
neutral lipids (NL) on the ER membrane, grow to form a spherical structure, and ultimately bud 
off  (Saka and Valdivia, 2012). Conceptually, the most significant difference between these 
processes is in the direction of budding. If the nascent droplet buds off outwards to the cytosol, it 
will become a cytosolic LD, whereas if it buds off into the ER lumen, the droplet will become a 
chylomicron. Given the similarity in the budding processes and the resulting similar composition 
– a triglyceride core surrounded by a phospholipid monolayer –  it is legitimate to hypothesize 
that similar membrane proteins could influence their formation. Thus, CPO might have a role in 
formation of both chylomicrons and lipid droplets, namely through cleavage of the C-terminal 



























Figure 2. Model for the formation of lipid droplets from the ER membrane. The accumulation of 
neutral lipid (yellow spheres) between the leaflets of the membrane will form a spherical 
structure that buds off. If the lipid droplet buds into the lumen, it will later fuse with an apo-B48-
phospholipid (PL) rich particle and form a chylomicron (CM). CPO (pink) is attached to the 
inner leaflet through a GPI anchor (yellow).  
 
2. Digestion  
The digestive processes involved in food breakdown and absorption involve a large 
number of structures, ranging from organs to accessory glands and include a wide array of 
enzymes. Digestion first begins in the mouth and moves through the stomach, aided by 
pancreatic secretions, until finally arriving to the small intestine, where chemical digestive 
processes continue to further break down dietary disaccharides, polypeptides, and emulsified fats 
(Tortora, 2009).  
 
a. Digestion in the brush border 
An important part of digestion in the small intestine occurs on the apical surface of 
enterocytes, more specifically at the brush border. Although the apical surface has been 
considered the hub for final digestion events, recent evidence points to an additional digestion 
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mechanism that occurs in the periapical space. Hooton et al. (2015) describe this mechanism, 
which lies on the vesicularization of the apical membrane and subsequent movement of the 
vesicles into the periapical space. This allows the brush border enzymes, now found on the 
membrane of the vesicles, to perform catalysis in the periapical space.  
As a key structure in the end stages of digestion, the small intestinal brush border is 
characterized by abundant and diverse enzymatic activity. The digestive enzymes present in the 
brush border finalize digestion of carbohydrates, proteins and lipids, and can be categorized into 
three major groups: disaccharidases /oligosaccharidases, peptidases, and lipases (Hooton et al., 
2015). Carbohydrate digestion is finalized in the brush border by action of disaccharidases such 
as sucrase, lactase, and maltase, which break down disaccharides into monosaccharides. In 
addition, α-dextrinase acts on small fragments of starch producing glucose (Tortora, 2009). 
Likewise, protein digestion is completed by aminopeptidase A, and dipeptidases, resulting in 
mostly free amino acids along with few dipeptides and tripeptides (Tobey et al., 1986). In 
contrast, lipid digestion can be considered finalized as lipids, which are assembled in spherical 
structures called micelles, arrive to the brush border (Tortora, 2009).  
 
b. Absorption in the brush border 
When nutrients are broken down into the most simple units (i.e. monosaccharides, fatty 
acids, and amino acids), they are able to pass through the enterocytes and eventually reach the 
blood or lymph. This process is known as absorption and it entails different forms of transport. 
For example, monosaccharides can be transported from the lumen through the apical membrane 
in two different ways. Glucose and galactose pass the apical membrane and enter the enterocytes 
via secondary active transport with Na+ through Sodium-Dependent glucose transporter 1 
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(SGLT1) while fructose is able to enter via facilitated diffusion through Glucose Transporter 5 
(Tortora, 2009). These monosaccharides leave through the basolateral membrane via facilitated 
diffusion using GLUT2 and are subsequently absorbed into the bloodstream through capillaries. 
In the case of amino acids, they may be actively transported into the enterocyte, or they will 
enter alongside Na+ via a symporter. As transporters discriminate amongst different classes of 
amino acids, a large cohort of transporters have been identified for neutral amino acids (BoAT1), 
lysine, arginine, ornithine, and cystine (rBAT, and Bo,+AT), proline and hydroxyproline 
(IMINO), aspartic acid and glutamic acid (EAAT3) (Broer, 2008). In contrast, dipeptides and 
tripeptides are transported via H+ symporter such as PEPT1 (Hooton et al., 2015). Amino acids, 
dipeptides and peptides collectively diffuse out of the enterocyte and enter the blood capillaries.  
At the brush border, monoglycerides and free fatty acids (e.g. 2,3-diacylglycerol and 2-
monoacylglycerol) diffuse out of the micelles into the enterocyte through the apical membrane, 
whereas glycerol will freely diffuse in and out of the enterocyte to enter the blood capillary 
(Meisenberg and Simmons, 2016). Unlike the aforementioned nutrients, which are simply 
transported in and out the enterocytes, free fatty acids undergo a series of chemical modifications 
while passing through the enterocytes (Bayly, 2014). Through multiple reactions, free fatty acids 
are converted into triglycerides. Triglycerides collectively assemble with phospholipids and 
apolipoproteins, thus giving rise to chylomicrons (Tortora, 2009). Due to their considerably large 
size (ranging from 200-1,000 mm in diameter) chylomicrons must exit the enterocytes via 
exocytosis and are further unable to enter the capillaries (Randolph and Miller, 2014). Instead, 
chylomicrons penetrate the adjacent lacteals through large pores located on their tips and are 
transported through the lymphatic system to peripheral tissues such as cardiac, adipose, and 
muscle (Randolph and Miller, 2014).  
 8 
3. Chylomicrons   
Over the past couple decades, there has been an increasing interest to study the formation 
and metabolism of chylomicrons. This has been mostly due to the recent detection of 
chylomicron upregulation in widespread diseases, namely type 2 diabetes and atherosclerosis 
(Dash et al., 2015). Clinical conditions involving dyslipidemia such as insulin resistance and type 
2 diabetes have been characterized by increased secretion of chylomicrons and apolipoprotein B, 
amongst other lipoproteins (Hussain, 2014). This finding has important implications, since 
dyslipidemia is one of the greatest risk factors for cardiovascular disease (Dash et al., 2015; 
Mooradian, 2009; Xiao et al., 2011), currently labeled as the number one leading cause of death 
in the U.S according to the most recent report by the CDC (Kochanek et al., 2019). Additionally, 
chylomicron dysregulation further extends to less common diseases, such as genetically 
transmitted familial hyperchylomicronemia syndrome (Brahm and Hegele, 2015) and familial 
dysbetalipoproteinemia (Koopal et al., 2017).  
Chylomicrons are the largest and least dense lipoproteins particles and are composed of a 
core of neutral lipids, namely triacylglycerols (85% of the total weight), enclosed by a 
phospholipid monolayer (8%) with about 1% of associated apolipoproteins (Demignot et al., 
2014). A form of apolipoprotein B, namely apoB48, is characteristic of chylomicrons and its 
presence serves as a marker to differentiate them from other closely-related lipoproteins 
(Nakajima et al., 2014). For example, while apoB48 is the main protein in chylomicrons, a 
longer form of the protein, apoB100, is the main protein in very-low density lipoproteins 
(VLDL) and low-density lipoproteins (Randolph and Miller, 2014). ApoB48 plays a key 
structural role in chylomicrons (Xiao, Stahel, & Lewis, 2018) while other apolipoproteins such 
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as ApoA-IV assemble on the surface of chylomicrons and play a role in their formation by 








Figure 3. Schematic illustration of a chylomicron. A phospholipid monolayer surrounds a core 
of neutral lipids which is mainly composed of triacylglycerols and sterol esters. Apolipoproteins 
apoB48 and apo-AIV located on the surface of the chylomicron play important structural and 
regulatory roles, respectively.  
  
While much is known about the physiology and composition of chylomicrons, their 
biogenesis is not entirely understood. The most recent model for chylomicron formation suggests 
a two-step assembly process. A lipid droplet buds off the inner leaflet of the ER membrane into 
the lumen, where it will fuse with a lipidated apoB48-rich particle in a reaction catalyzed by 
microsomal triglyceride transfer protein (MTP), eventually giving rise to a pre-chylomicron (Fig. 
4; Demignot et al., 2014). After this, the pre-chylomicrons are assembled into pre-chylomicron 
transport vesicles (PCTV) and trafficked to the Golgi apparatus (Cartwright and Higgins, 2001; 
Demignot et al., 2014).  
 
4. Lipid droplets 
Lipid droplets (LDs) and chylomicrons are formed by similar mechanisms. When a lipid 
droplet buds off to the ER lumen, it will give rise to a chylomicron; however, if it buds off to the 
cytosol, it will become a cytosolic lipid droplet. LDs constitute the major type of cellular 
organelle that stores excess neutral lipids namely triacylglycerols and sterol esters (Vevea et al., 
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2015). This storage mechanism is considered protective, since it avoids disruption of membrane 
integrity by over-accumulation of neutral lipids (Welte, 2015). In eukaryotes, de novo formation 
of LDs occurs due to an accumulation of neutral lipids, on defined regions between the leaflets 
of the ER (Roux and Loewith, 2017). The most accepted model proposes that the nascent LD 
forms a lens, which grows in size until the LD is fully formed and released (Saka and Valdivia, 
2012). LDs that bud off to the cytosol and accumulate on the apical side of the enterocyte, where 
they will serve as transient lipid reservoirs (Hussain, 2014).  
Nonetheless, LDs are versatile as they have been recently found to have functions beyond 
lipid storage. Several studies have identified many LD functions such as storage of vitamins and 
molecules involved in cellular signaling, as well as assembly of viruses (Saka and Valdivia, 
2012; Welte and Gould, 2017). For example, Welte and Gould (2017) discuss the involvement of 
LDs in lipid signaling by means of storage of eicosanoid precursors. Although these precursors, 
namely arachidonic acid rich triglycerides, may be obtained through the breakdown of 
phospholipids, LDs represent an important additional source. Moreover, LDs constitute major 
sites of vitamin A storage (in the form of retinyl esters) with about 80 % of the total reservoir 
found in hepatic cells (Welte & Gould, 2017). Cholesteryl esters also stored in the LD core serve 
as sources of cholesterol for synthesis of steroid hormones (Kraemer et al., 2013). A well-studied 
case of LDs acting as assembly platforms during viral infections is that of hepatitis C. Studies 
have shown that localization of the virus core protein on the surface of LDs is necessary for 
assembly of new immature viruses (virions) on the host cell (Saka and Valdivia, 2012). Due to 
their many physiological roles, LD formation is tightly regulated. Accumulation of lipid droplets 
has been associated with major diseases (e.g. type II diabetes, obesity, atherosclerosis, and fatty 
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liver disease) which has led to an increasing interest in studying their physiology (Meyers et al., 
2017; Welte and Gould, 2017). 
Despite continuing efforts to elucidate the molecular processes behind LD biogenesis, 
many questions remain unanswered today (Hussain, 2014; Roux and Loewith, 2017; Wilfling et 
al., 2014). Yeast represents a well-studied eukaryote model for lipid metabolism, and its use in 
the study of this metabolism is suitable given its high conservation in both humans and yeast 
(Karathia et al., 2011). To date, the yeast model has identified many key proteins that participate 
in LD formation. For example, Lor1p, a putative homolog of the human lecithin cholesterol 
acyltransferase (LCAT), mediates the conversion of diacylglycerol to triacylglycerol (Oelkers et 
al., 2000; Roux and Loewith, 2017). The model of lipid formation in yeast is the most detailed 
model described to date; however, a number of studies consider this model to be incomplete 
since it has failed to describe crucial events in droplet formation, such as the excision of the 
nascent LD, thus pointing to a need for further research in this area (Meyers et al., 2017; Roux & 











Figure 4. Schematic illustration of a generic LD. A phospholipid monolayer surrounds a core of 
neutral lipids (NL) which is mainly composed of triacylglycerols and sterol esters. While 
perilipins (PLIN) and Rab18 proteins are abundant on the LD surface, other LD-associated 




In this study, I investigate a hypothesis initially made by Burke et al. (2018), which 
suggested that CPO is involved in the formation of chylomicrons. In addition, I build on previous 
work from Burke et al. (2018) by evaluating the association of CPO and LDs in undifferentiated 
human colon carcinoma (Caco-2) cells. Here, I show that CPO stably-expressing Caco-2 cells 
exhibit CPO association with both LD and apoB, with association in LDs being significantly 
dependent upon time elapsed after feeding. A comprehensive analysis of CPO expression data 
showed prominent expression in the ileum and modulation of expression in ulcerative colitis and 
Crohn’s disease as well as expression in basophils and Peyer’s patches, which suggest promising 


































1. Compilation of CPO expression data 
CPO expression data was obtained from several databases which included RNA 
sequencing (RNA-Seq) and microarray data. RNA-Seq data was obtained from publicly 
available datasets such as Human Protein Atlas (HPA; www.proteinatlas.org) which allow access 
to transcriptomics data, including a compilation of data from prominent datasets such as 
Genotype-Tissue Expression (GTEx), HPA, and FANTOM5 CAGE (Pontén et al., 2011). 
Additionally, data was gathered from the Bgee website (Bastian et al., 2008), which compiles 
RNA-seq data from the Gene Expression Omnibus (GEO; NCBI) and GTEx. Genevestigator, a 
powerful transcriptomics analysis tool (Hruz et al., 2008; Zimmermann et al., 2005), was used to 
access the mRNASeq_HUMAN_GL-1 platform, thus providing an additional RNA-Seq dataset. 
Microarray data was also included in the expression analysis due to its notable prevalence 
in transcriptomic profiling.  Microarray data, although providing less sensitivity for low-
expression genes, constitutes a reliable choice (Zhao et al., 2014). The microarray data was 
retrieved from three platforms. The first one was the Affymetrix Human Genome U133 Plus 2.0 
Array, a microarray platform in Genevestigator. The second one was the Bgee website, which 
compiled data from the GEO and the ArrayExpress from European Molecular Biology 
Laboratory-European Bioinformatics Institute (EMBL-EBI). The third one was the Gene 
Expression database of Normal and Tumor Tissues (GENT2; www.gent2.appex.kr) database, 
which includes gene expression data from healthy and cancerous tissues. GENT2 compiles 
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affymetrix microarray data from U133 Plus 2.0 as well as the U133A platforms (Park et al., 
2019).  
 
2. Site-directed mutagenesis 
The goal of site-directed mutagenesis was to introduce a point mutation, E310Q, into 
plasmid DNA (pcDNA; Fig. 5). First, custom primers were manually designed. To do this, the 
human CPO (hCPO) sequence was translated into its amino acid sequence using the EMBOSS 
explorer interface. The amino acid of interest E310 was located and aligned with the 
corresponding codon on the forward DNA strand. Overlapping primers were created following 
ThermoFisher’s protocol and included the following criteria: 15 base pair complementary 
regions with the point mutation located in the middle along with non-overlapping bases at the 3’ 
end (underlined). The final primer sequences were hCPO-E310Q-F3 5’- 
CGTTTCAGCTGAGGGACAGTGGAAC-3’; hCPO-E310Q-R3 5’- 
CCCTCAGCTGAAACGTATATGAGAAGGG-3’. PCR amplification was used to create the 
mutation, and two 50 μL reactions were prepared. Each reaction contained 1.5 μL Platinum 
Superfi Polymerase (Thermofisher), 2mM dNTP mix,  30 μL 5x Superfi buffer (Thermofisher), 1 
μL template DNA, and 0.5 μM of each primer, and one reaction contained 3% DMSO to enhance 
amplification. A BioRad 100 Thermocycler was used with the following program conditions: 
98°C (30 s), 98 °C (10 sec), 67.1 °C (10 sec), 72 °C (195 s) repeated for 25 cycles, and final 
extension at 72 °C for 5 min. The PCR products were resolved on a 1% agarose gel and 
visualized with ethidium bromide/UV. After confirmation of amplification, PCR products were 
digested with Dpn1 to remove the parental plasmid DNA, which did not contain the mutations.  
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3. Ethanol precipitation   
To purify the digested PCR product, ethanol precipitation was performed. The PCR 
product (40 μL) was mixed with 0.3 M NaAC (pH 5.2), 250 μL of cold 100% ethanol (-20 °C), 
and 50 μL of ddH2O. Following incubation at -80 °C for 30 min, the sample was centrifuged at 
21,130 g for 30 min. The precipitate was rinsed with 500 μL of 70% ethanol, centrifuged 21,130 
g for 15 min, and resuspended in 10 μL ddH2O. 
 
4. Bacterial transformation 
DH5α competent E.coli cells were transferred from the -80 °C freezer and allowed to 
thaw on ice for 15 min. Two controls, a positive and a negative, were prepared by addition of 25 
μL DH5α cells to 5 μL pcDNA [hCPO] (1 ng/μL) and 5 μL ddH2O respectively. Additionally, 
two experimental samples, one with 5 μL digested PCR product and one with 5 μL of the 
digested + purified PCR product were prepared by addition of 50 μL DH5α cells. The samples 
were gently mixed, incubated on ice for 30 min, and heat shocked for 40 s at 42 °C. Following a 
5 min incubation on ice, 200 μL of sterile Luria Broth (LB) were added and mixed by stirring 
with the pipet tip. The samples were incubated at 37°C for 60 min and then spread on 
LB/ampicillin plates, which were incubated at 37 °C overnight. The plates were inspected for 
colony growth 16 h following plating.  
 
5.    Plasmid preparation by NID method  
Colonies were randomly selected from both the plates: three colonies from the plate with 
digested DNA and three colonies from the plate with digested + purified DNA. In culture tubes, 
2 mL of sterile LB broth and 2 μL ampicillin were mixed. The colonies were individually 
 16 
scooped from the plates with a flamed pipet tip and resuspended in the mixture contained within 
the culture tube. The tubes were later placed in a shaking incubator at 37 °C for 20 h.  
A larger working stock of pcDNA-hCPO E310Q was produced by a large-scale bacterial 
transformation. The volumes of reagents and pcDNA (see above) were reduced by 5-fold, while 
bacterial cultures were grown in culture tubes with about 5-fold the volume of LB broth and 
ampicillin. After 12 h of incubation at 37°C, 1 mL of the culture was transferred to a flask 
containing 50-fold volume of LB broth and ampicillin and grown for 8 additional hours. 
The contents of the culture tubes were transferred to 2 mL tubes and centrifuged at 
21,130 g for 30 s. The pellets were resuspended in 150 μL of extraction buffer (5% sucrose, 50 
mM EDTA, 50 mM Tris pH 8.0, 0.75 M NH4Cl, 0.5% Triton X-100, 100 μg/mL lysozyme, 25 
μg/mL RNAase A) and incubated at 65 °C for 5 min. Following centrifugation (10 min at 21,130 
g), the pellet was removed with a sterile toothpick and mixed with 120 μL of isopropanol by 
vortexing. The mixture was centrifuged at 4,602 g and the supernatant was subsequently 
discarded. To the tube, added 500 μL 70% ethanol was added and it was centrifuged at 21,130 g 
for 10 min. In order to remove any supernatant left, the bulk of it was pipetted out and then the 
pellet was allowed to air dry for 10 min. The pellet was resuspended in 50 μL of EB buffer.  
In the large-scale NID plasmid prep, the contents of the culture tubes were transferred to 
50 mL tubes and centrifuged (3,000 g for 5 min at 0 °C). The pellet was resuspended in 5 mL of 
extraction buffer and the tube was incubated in a 65 °C water bath for 8 min. Following 
centrifugation (19,000 g for 30 min at 0 °C), the supernatant was transferred to a new tube, 
mixed with 7 mL of isopropanol. After the sample was centrifuged (19,000 g for 15 min at 0 °C), 
the pellet was resuspended in 1.5 mL of 70% ethanol and centrifuged at 15,000 rpm for 5 min. In 
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order to remove any supernatant left, the bulk of it was pipetted out and then the pellet was 
allowed to air dry for 10 min. The pellet was resuspended in 400 μL of EB buffer.  
 
6. DNA quantification 
DNA isolated from each of the six E.coli colonies was visualized on a 1% agarose gel. 
Each sample loaded contained 1 μL template DNA, 2 μL 6x loading dye and 7 μL ddH2O. An 
image of the gel taken with AlphaImager imaging system was analyzed using ImageJ (NIH). 
This image processing program allowed quantification of the DNA by comparison to the marker 
lane (Tridye 1kb).  
Spectrophotometry was used to calculate the quantity and purity of the pcDNA-hCPO 
E310Q, known as the ratio of absorbance at 260 nm over the absorbance at 280 nm 
(A260/A280). In a UV compatible cuvette, mixed 2 μL template DNA and 198 μL ddH2O were 
mixed and absorbance measured at 260 nm and 280 nm. 
 
7. Sanger sequencing 
In accordance with Genescript’s requirements (NJ, USA), only those DNA samples with 
optimal yields were selected and prepared for sequencing. Preparation was done by addition of 5 
μL of T7 primer (10 μM) to 10 μL of template DNA. Sanger sequencing and subsequent 
alignment to the hCPO sequence (Accession: NM_173077.3) using BLAST allowed 






Figure 5. Site-directed mutagenesis is used to create the mutant pcDNA-hCPO E310Q. A set of 
custom partially overlapping primers with 3’ overhangs (blue arrows) containing single point 
mutations (red) were used to amplify the plasmid. Transformation into competent cells allows to 
produce large quantities of the primer, which are subsequently purified. Presence of mutation is 
confirmed via Sanger sequencing 
 
 
8. Maintenance of Caco-2 cell line  
Caco-2 were grown in an incubator set to 37°C and 5% CO2  and maintained in 
Dulbecco’s Modified Eagle Medium supplemented with 10% Fetal Bovine Serum (Sigma 
Aldrich) and 1% Penicillin/Streptomycin (Sigma Aldrich). The cells were passaged at 1:5 or 1:10 
(vol/vol) when ≅ 80 % confluency was reached. To passage the cells, the media was removed 
and the cells were washed twice with Dulbecco’s modified Phosphate Buffered Saline (PBS; 
Sigma) and trypsinized (Trypsin-EDTA 1x; Sigma) for 6 min in the incubator. The cells were 
subsequently resuspended in fresh complete medium and seeded at desired density. Medium was 
regularly changed every 48 h. 
 
9. Transfection of Caco-2 cells  
Caco-2 cells were seeded in a 6-well plate at a density of 1.5 x105/well with 2 mL of 
complete medium 24 h before transfection. Once at room temperature, the reagents were mixed 
in a sterile 1.5 mL tube as follows: first, 200 μL of serum-free DMEM were mixed with 3 μg 
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total plasmid DNA (Fig. 6). Second, the diluted DNA was mixed with 9 μL Polyethylenimine 
(25kD linear; Polysciences, cat# 23966-2). After incubation at room temperature for 15 min, the 
mixture was added to the cells and the plate was mixed 6-8 times. Cells were incubated at 37°C 
and 5% CO2 for 48 h.  
 
10. Selection of stable transfectants  
Post-transfection, the cells were counted on a hemocytometer and subcultured at the desired 
density in 100 mm dishes. Selection of stable transfectants began 24 h after with addition of 
Geneticin (G418) at 0.8 mg/mL to the medium (Fig. 6). Medium was changed and supplemented 
with G418 three times a week for three weeks. Resistant clones were observed under a bright-
field microscope and those exhibiting healthy morphologies were marked for further expansion. 
To isolate the individual clones, the dishes were washed twice with 5 mL of Dulbecco’s PBS and 
a cloning disc previously soaked on trypsin for 15 min was placed directly on top of each 
selected clone. After incubation at 37°C for 5-6 min, the discs were transferred to a 24-well plate 
containing 0.5 mL medium and mixed 6-8 times. Medium was changed 2-3 times a week. As 
G418-resistant clones reached moderate confluences (50-70%), they were transferred to 6-well 
plates, where they were maintained with addition of fresh medium three times a week. A 
population of stable transfectants were maintained in 100 mm dishes with complete medium 
supplemented with 0.8 mg/mL G418. 
 
11. Preparation of cell extracts for western blotting analysis  
G418-resistant clones of stably transfected cells were trypsinized in 1 mL of trypsin and 
resuspended in 1 mL of complete medium. Resuspended cells were transferred to a 2 mL tube 
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and kept on ice, and 0.1 mL were used for cell counting. The resuspended cells were centrifuged 
for 1 min at 5,000 g. After removing the supernatant, 2 mL of PBS were added and the tubes 
were vortexed and centrifuged for an additional minute. The volume of cold lysis buffer (150 
mM NaCl, 20 mM Tris pH 7.5-8.0, 1% Triton X-100, 2 mM EDTA, 1 mM PMSF) added to the 
pellet was proportional to the number of cells in the extracts. Samples with the highest cell count 
were resuspended in 300-400 μL of buffer, while 70-100 μL of buffer was used for samples with 
the lowest cell counts. The mixtures were passed through a 22 G ½ needle 8-10 times. After 
centrifugation at 21,130 g for 2 min, the supernatant (containing the cell extracts) was transferred 
to a new tube and stored at -20°C overnight.  
 
12. Western blotting  
Samples for western blotting by mixing 20 μL cell extracts with 5 μL 5x sample buffer 
(0.375 M Tris pH 6.8, 12% SDS, 60% glycerol, 0.6 M DTT, 0.06% bromophenol blue). The 
samples were heated for 3 min at 95 °C and 15-20 μL were loaded onto a 10% SDS-PAGE gel 
and ran at 160V for 65 min. The gel was subsequently incubated in 1X transfer buffer (25 mM 
Tris Base, 192 mM glycine, 10% MeOH) and transferred for 60 min at 100 V onto a 
nitrocellulose membrane, then blocked in a solution of 5% non-fat milk in TBST (Tris-buffered 
saline, 0.1% Tween 20). Incubation of the nitrocellulose membrane was done with rabbit RP3-
CPO (Triple Point Biologics; 1:5000 dilution) as the primary antibody and HRP conjugated anti-
Rabbit IgG (Cell Signaling Technology; 1:2000 dilution) the secondary antibody. Nitrocellulose 
was treated with Lumi-GLO chemiluminescent reagent (Cell Signaling Technology) for 1 min 





Figure 6. Illustration of transfection and selection protocols. Plasmid DNA containing WT or 
E310Q CPO (in red) is added to the cell cultures (pictured: 100mm culture dish). Cell cultures 
are treated with geneticin (G418) 2-3 times a week. A population of resistant clones is 
transferred to 24-well plates and expanded. Cell extracts from clones that were successfully 
expanded are analyzed for CPO expression via western blotting. 
 
13. Immunofluorescence 
Coverslips were incubated with Poly-D-lysine in PBS (1 mg/mL) for 1 h, washed with 
sterile H2O, and dried under UV light for 1h. Caco-2 cells from a pooled polyclonal culture 
containing hCPO WT transfectants were seeded at 1.5 x105 cells/well in 6-well plates containing 
poly-D-lysine coated coverslips. When cells reached 60-80% confluency, they were washed 
three times with PBS, fixed in 4% paraformaldehyde for 10 min at room temperature, and then 
washed three times for 5 min on the rocker. The cells were permeabilized in 0.1% Triton X-100 
in PBS for 15 min, washed, and blocked with 5% bovine serum albumin in PBS for 35 min. 
Primary antibodies RP3-CPO (Triple Point Biologics, cat.# MAB41241-100; 1:1000 dilution) or 
human Apolipoprotein B (R&D Systems, 1:25 dilution) were diluted in 5% bovine serum 
albumin in PBS and added directly onto the coverslip and incubated for one hour. After washing 
three times with PBS, the cells were incubated with secondary antibodies anti-mouse Alexa 
Fluor 488 and/or anti-rabbit Alexa Fluor 555 (Cell Signaling Technology, 1:1000 dilutions). 
Coverslips were washed three times and then mounted with 12 μL of aqueous mounting medium 
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(PBS containing 1 mg/mL p-phenylenediamine hydrochloride and 1 μg/ml DAPI). To stain lipid 
droplets, 4 μL BODIPY (Invitrogen) was added to the coverslip during the penultimate washing 
step and incubated on the rocker for 13 min. The slides were allowed to dry in a cool, dark place 
overnight and were later stored at 4°C. 
Images of thirteen fields of view containing at least one CPO-expressing cell were 
captured with a fluorescence microscope. To evaluate association, % values (LD:CPO or 
apoB:CPO) were normalized using the arcsin transformation and subsequently analyzed by a 
one-way ANOVA. 
 
14. Carboxypeptidase Assay  
Twenty microliters of HEK293T cell extracts were incubated with 100 μL 0.5mM Fa-EE 
carboxypeptidase substrate in a 96 well plate and their A340 was measured at 24°C every min 























1. Analysis of CPO expression  
In order to better understand the potential biological role of CPO, an in-depth analysis of 
data from several gene expression databases was performed. Investigating the levels of 
expression across organs and tissues can potentially shed some light on the biological function of 
this protein. Thus, a comprehensive collection of CPO expression data is an appropriate 
approach to accomplish this.  
Protein expression is commonly similar to RNA expression which can be quantified 
using transcriptomic techniques (Wang et al., 2009). These transcriptomic techniques present a 
high-throughput, highly sensitive sequencing method that allows quantitative assessment of the 
expression of a gene in a given tissue or cell line (McGettigan, 2013). This is achieved by 
measuring the RNA transcript abundance found for a given protein-coding gene. For the 
purpose of the expression analysis in this study, RNA sequencing (RNA-Seq) and microarray 
data were compiled. 
 
a.  CPO expression in the small intestine 
CPO exhibits its highest levels of expression in the small intestine, as found in RNA-Seq 
and microarray databases. The consensus expression found in proteinatlas.org, which includes 
data from HPA, GTEx and FANTOM 5, collectively denote the small intestine as the tissue with 
highest expression in humans (Fig. 7A-C). In addition, HPA indicates that CPO expression is 
tissue enriched, as it is at least 4x greater than in any other tissue. More specifically, microarray 
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data from the Affymetrix Human Genome U133 Plus 2.0 Array platform revealed that CPO is 
overwhelmingly expressed in the ileum (Fig. 8B). The affymetrix microarray data was found to 
closely match the data found in the mRNASeq_HUMAN_GL-1 platform, both referring to 
location and relative levels of expression (Fig. 8A). Notably, in the mRNASeq platform the 
aforementioned ileal epithelium is referred to as the terminal ileal epithelium. High levels of 
expression were detected in the ileal epithelium, also known as mucosa. RNA-Seq data from 
Bgee further suggests that within the ileal mucosa, lymphoid structures known as Peyer’s 
patches, are the anatomical entity with the highest relative CPO expression (Fig. 7D).  
 
b. CPO expression in other tissues 
In addition to the small intestine, CPO exhibits varying levels of expression in other 
tissues including male reproductive tissues, brain, adrenal, and thyroid (Figs. 7,8). According to 
the HPA and FANTOM 5 databases, the epididymis is the tissue with the second highest CPO 
expression (Fig. 7A,C). This claim is supported by the Affymetrix Human Genome U133 Plus 
2.0 Array platform, which names two regions with medium expression levels, namely the 
epididymal cauda and corpus (Fig. 8B). Although the mRNASeq platform fails to include the 
epididymis, it mentions another male reproductive structure, the testis, with medium-low 
expression (Fig. 8A).  
The brain exhibits widely spread CPO expression with varying levels of expression. For 
example, the Affymetrix Human Genome U133 Plus 2.0 Array platform indicates that medium 
expression levels are found in a variety of neural structures. Within the medium expression level 
range, the cingulate cortex neuron had the highest expression, followed by the hippocampus 
pyramidal neuron, basal ganglia, entorhinal cortex large stellate neuron, and the hypothalamus 
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(Fig. 8B). While the Affymetrix U133 platform suggests medium expression in multiple brain 
tissues, RNA-Seq data suggests low to background level expression in most of those tissues (Fig. 
8A). 
RNA-Seq data from Bgee and mRNASeq_HUMAN_GL-1 report that the caudate 
nucleus and caudate-putamen complex, respectively, as the sites with highest expression in the 
brain; nonetheless, the expression levels in both structures appears to be modest (Figs. 7D, 8A). 
Further, the mRNASeq_HUMAN_GL-1 platform reports medium expression in the 
hippocampus, which contrasts with the background level expression detected by RNA-Seq from 
GTEx (Fig. 8A, 7B, respectively). GTEx and FANTOM 5 do not report regional specificity nor 
specific distribution of CPO in the human brain. Nonetheless, both databases report low 
expression in the ganglia while GTEx also reports expression in the pituitary gland (Fig. 7A,C). 
Taken together, the data points to an overall low presence in the brain. 
 Low levels of CPO expression are seen in adrenal tissues. The adrenal gland cortex 
presents a moderate expression score, as determined by RNA-Seq databases from Bgee (Fig. 
7D). Expression in the adrenal gland is also reported in the mRNASeq_HUMAN_GL-1, 
Affymetrix Human Genome U133 Plus 2.0 Array, and GTEx platforms (Fig. 8A,B; Fig. 7A). 
While overall expression in the adrenal gland is moderate, it appears to be slightly greater in the 
fetal stage than in adulthood (Fig. 8A,B). Nonetheless, it is important to note that none of the 
aforementioned platforms report expression in both fetal and adult, thus making it challenging to 
establish a fair comparison across platforms. Additionally, low expression is detected in the 
thyroid gland, as reported in and GTEx, HPA, Bgee, and Affymetrix Human Genome U133 Plus 






Figure 7. CPO is largely expressed in the small intestine and has low expression in a number of 
other tissues. CPO expression levels were determined by RNA-Seq data from HPA (A), GTEx 
(B), FANTOM 5 (C) datasets and both RNA-Seq/Affymetrix from the BGEE website (D). The 
small intestine is collectively reported as the tissue with highest CPO expression (A-D), and 
expression in other tissues is considerably lower than in the small intestine (A,B,C). Expression 
scores from Bgee have been normalized (0-100) from expression call values across genes and 
conditions within the species, with scores below ~80 arguably considered as moderate 










































Figure 8. CPO is expressed in blood cells, male reproductive, brain, and adrenal tissues, with 
highest expression in the ileum mucosa and ileal epithelial cells. Gene expression is reported as 
absolute levels in log2 scale, with low, medium, and high ranges specific to the 
mRNASeq_HUMAN_GL-1 platform (A) and the Affymetrix Human Genome U133 Plus 2.0 Array 
platform (B). In the affymetrix microarray platform (B), the mean value of the ileal mucosa 
“13.92” (shown as log2) equals “35,075” in linear scale, which compares to “7.25” (shown as 
log2) and “231.77” in linear scale according to the mRNASeq platform (A). Data is modified 





c. CPO expression in the Blood 
The blood was found to be the third highest tissue displaying significant CPO expression. 
mRNA expression data from the HPA database revealed enrichment of CPO expression in 
granulocytes, specifically the basophils (Fig. 9). Similarly, the mRNASeq_HUMAN_GL-1 
platform also reports medium levels of CPO expression in low density basophils (Fig. 8A). In 
contrast, the Affymetrix Human Genome U133 Plus 2.0 Array platform reports a wider variety 
of blood cells with CPO expression ranging in the medium levels, with bone marrow plasma 
cells at the highest, then CD4 t-large granular lymphocyte, followed by T-cells, neutrophils, and 
eosinophils (Fig. 8B). A small, almost negligible level of expression in eosinophils is also found 
in the HPA database (Fig. 9).  
Interestingly, granulocytes are white blood cells, known to play a crucial role in 
immunity. More specifically, basophils are involved in inflammatory responses such as allergic 
reactions (Wedemeyer et al., 2000). Thus, CPO expression in the basophils alludes to a potential 
role of CPO in immunity. Moreover, the expression in Peyer’s patches, known to play a role in 











Figure 9. CPO expression in blood cells. Out of 29 total cell types analyzed by RNA-Seq, only 
three showed CPO expression, with basophils exhibiting the highest levels of expression at 8.9 
pTPM. Modified from http://proteinatlas.org. 
 
 29 
d.  CPO expression in cell lines  
While CPO is expressed across a variety of cell lines, its highest levels of expression are 
detected in cancer derived cell lines. RNA-seq data from the HPA database reports four cell lines 
where CPO is moderately expressed, and three of which are human cancer cell lines (Fig. 10A).  
These cancer cell lines are NB-4, from the bone marrow, ASC diff, from sarcoma, BEWO, from 
the brain, and the non-cancerous telomerase immortalized cell line hTCEpi, originating from the 
cornea. The mRNASeq_HUMAN_GL-1 platform cites four different cell lines with medium 
expression, with HD-iPS4-HTT at the highest followed by NCl-446, SNU-349, and WA09 (Fig. 
10B). HD-iPS4-HTT constitutes induced pluripotent stem cells from Huntington’s disease 
patient, while WA09 is a human embryonic stem cell line. The remaining two, NCl-446 and 
SNU-349 are cancer cell lines, from the lung and renal carcinoma respectively. A lung cancer 
metastatic cell line is reported to have high levels of CPO expression, according to the 
Affymetrix Human Genome U133 Plus 2.0 Array platform (Fig. 10C). Additionally, medium 
CPO expression levels are reported in embryonic stem cell WA07, mammary epithelial cell line 
76N-RHOA, and bone marrow metastatic cancer cell line Rh30 (Fig. 10C).  
Because CPO has prominent expression in the small intestine and basophils, we sought to 
investigate this expression in cell culture models, namely Caco-2, which has an intestinal 
phenotype, and a human basophil cell line, KU812. Both cell lines presented low to no 
expression according to mRNASeq_HUMAN_GL-1 and Affymetrix Human Genome U133 Plus 
2.0 Array platforms. Overall, Caco-2 has a more consistent record of expression, with medium-
low expression reported by the Affymetrix Human Genome U133 Plus 2.0 Array platform and 
low expression reported by the mRNASeq_HUMAN_GL-1 platform (Fig. 10B,C, respectively). 
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In turn, KU812 has medium CPO expression according to the affymetrix microarray platform, 
whereas the mRNA-seq platform notes no expression (Fig. 10C; 10B, respectively).  
 
 
Figure 10. A diverse number of cell lines, mostly cancer derived, have moderate levels of CPO 
expression.  RNA-seq data from HPA (A) shows three cancer cell lines with important CPO 
expression (in pTPM), NB-4, ASC diff and BEWO, while the mRNASeq_HUMAN_GL-1 platform 
(B) includes two, NCI-H446 and WA09 with medium expression (in absolute levels in log2 scale). 
The Affymetrix Human Genome U133 Plus 2.0 Array (C) is the only platform to report a cell line 
(CL-H446) with high CPO expression. Data modified from Genevestigator and 
http://proteinatlas.org.  
 
e.  CPO expression and associated pathology  
A number of pathological disorders characterized by chronic inflammation of the 
digestive tract have shown abnormal CPO expression levels. These pathological disorders are 
considered subtypes of the inflammatory bowel disease (IBD) and include Crohn's disease and 
ulcerative colitis (Baumgart and Sandborn, 2012). Since they share many symptoms, these two 
pathologies are mainly differentiated by their localizations. Crohn's disease can develop 
anywhere along the digestive tract, while ulcerative colitis is confined to the colon (Baumgart 
and Sandborn, 2012; Head and Jurenka, 2003). Clinical data retrieved from Genevestigator 
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mRNA-Seq (mRNASeq_HUMAN_GL-1) and affymetrix microarray (Human Genome U133 
Plus 2.0 Array) platforms revealed two main sites with high CPO expression where such 
pathological conditions have been reported. 
The first site was identified as the ileal mucosa and was characterized by the highest CPO 
expression (Fig. 11A, 12A). A study by Arijs et al. (2009; Genevestigator ID (G-ID): HS-00598) 
assessed expression in healthy patients and Crohn’s disease patients who were receiving 
Infliximab treatment. The results of the study suggest a pattern of decreased expression in 
Crohn’s disease patients (Fig. 11B).  
Similarly, the ileal epithelium, which was ranked second highest in expression in the 
affymetrix microarray platform, reported high-medium expression in all patients (n = 6) 
diagnosed with Crohn's disease (Funke et al., 2009; G-ID: HS-01050; Fig. 11C). These levels of 
expression in diseased patients appear to be less than those detected in healthy patients, 
coinciding with the presumed trend observed by Arijs et al. (2009; G-ID: HS-00598) in the ileal 
mucosa. Furthermore, a large study conducted by Howell et al. (2018; G-ID: HS-03228) reported 
expression ranging from high to medium in 17 patients with IBD (n = 17) (Fig. 12B). Upon 
analysis of the individual cases, it was found that all the patients with ulcerative colitis (n = 7) 
exhibited higher expression levels than those with Crohn's disease (n = 10; Fig. 12C). Likewise, 
most Crohn's patients exhibited decreased expression versus healthy individuals (n = 6).  
Additionally, ulcerative colitis appears to modulate CPO expression, as seen by a 
differential modulation in ileal tissue. For example, one study (Haberman et al., 2014; G-ID: HS-
01562) reported CPO expression was modestly downregulated in ileal tissue of young patients 
(aged 0-10 years old) with ulcerative colitis (Fold Change (FC): -1.63; p < 0.001) (Fig. 12C). In 
the same study, older diseased patients (10-17 years old) showed increased expression than 
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younger patients (FC: +1.61; p < 0.001), indicating that CPO expression specifically in the ileum 
of diseased patients may be age dependent.  
In contrast, CPO is more drastically regulated in Crohn’s disease. One study by Peck et 
al. (2015; G-ID: HS-01505) found a very large upregulation of the CPO gene in colon tissue of 
patients with bowel stricture (B2) and penetrating (B3) Crohn's disease (FC: 12.15 and 4.28, 
respectively; p < 0.001) (Fig. 12C). Conversely, CPO was significantly downregulated in the 
ileum of diseased pediatric patients, as reported in study G-ID: HS-01562 (Haberman et al., 
2014). More specifically, the downregulation was greater in patients aged 10-17 (FC: -4.45; p < 
0.001) than in patients aged 0-10 (FC: -3.57; p < 0.001).  
Although CPO is modulated in both IBD conditions, ulcerative colitis and Crohn’s 
disease, the data indicates a much more evident relationship between CPO and Crohn’s disease. 
When comparing CPO expression in both pathologies, a study (G-ID: HS-01562; Haberman et 
al., 2014) found that CPO is significantly more downregulated in ileal tissue in Crohn’s disease 
versus ulcerative colitis (Fig. 12C). In fact, this difference is greater in Crohn’s patients who 
exhibit deep ulcers (FC: -4.51; p < 0.001) than in those with a clinically affected colon (FC: -
2.13; p < 0.001) (Fig. 12C). Downregulation in Crohn’s disease was more moderate in younger 
patients (FC: -1.38; p = 0.033; Fig. 12C). 
In addition, moderate CPO expression has been reported in several pathologies, including 
cancer. In an analysis of expression across 72 paired tissues, the GENT2 database showed that 
CPO was significantly overexpressed in cancerous small intestinal and blood tissue (p = 0.026 
and p < 0.001, respectively) (Fig. 13). Colon carcinoma and lymphoma, although based on a very 
small sample size (n = 2), exhibit high CPO expression (Fig. 11A). Other pathologies with 
medium expression levels were the monoclonal gammopathy of undetermined 
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significance (MGUS) and multiple myeloma. Furthermore, a study on adrenal cortical carcinoma 
(G-ID: HS-01616; Zheng et al., 2016) found a moderate downregulation in patients on stage IV 




Figure 11. CPO expression data from the Affymetrix Human Genome U133 Plus 2.0 Array 
platform. The platform identifies high levels of CPO expression the ileal mucosa and ileal 
epithelium cells, with a trend indicating decreased expression in Crohn’s disease patients. 
Microarray data from Genevestigator includes CPO expression levels across 1,066 
anatomy/cancer entries, and identifies the ileum as the primary site of expression (A). Two 
studies, G-IDs: HS-01050 and HS-00598, found decreased expression in the ileal epithelium 
cells (B) and ileal mucosa (C) of patients with Crohn’s disease. The experimental treatment in 
study HS-00598 consisted of a single Infliximab dose (5mg/kg body weight) (C). Values shown 








Figure 12. CPO expression data from the mRNASeq_HUMAN_GL-1 platform. This RNA-Seq 
platform reports CPO expression levels across 624 anatomy/cancer entries, and identifies the 
ileum as the primary site of expression (A). A study (G-ID: HS-03228) reported decreased levels 
of expression in IBD patients, with ulcerative colitis patients exhibiting higher expression than 
Crohn’s (B). Values shown are absolute expression levels (TPM) in log2 scale. C. CPO 
expression is differentially modulated in IBD patients, with older patients (aged 10-17) 
presenting stronger regulations than younger patients (aged 0-10). CPO expression is regulated 
more strongly in Crohn’s disease patients than in ulcerative colitis patients. Log2-ratio 
represents the difference between the average log2 expression for experimental and control 












Figure 13. CPO is overexpressed in cancerous small intestinal and blood tissues. In an analysis 
of expression across 72 healthy and cancerous “paired” tissues, the GENT2 database reported a 
significantly increased log2 fold-change in small intestine (p = 0.026) and blood tissue (p < 
0.001). Modified from http://gent2.appex.kr/gent2. 
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2. Creation of the hCPO E310Q mutant 
Unlike other members of the M14 family, CPO is expressed as a constitutively active 
enzyme, as it does not need to undergo proteolytic cleavage to be activated (Garcia-Guerrero et 
al., 2018). Thus, to control for enzyme activity and protein expression, it is useful to employ an 
inactive CPO mutant as a means of comparison against the fully active (WT) CPO. This may be 
achieved through mutagenesis of a key catalytic residue, namely E310, which will effectively 
suppress the catalytic ability of CPO. An hCPO E310Q mutant was created with the ultimate 
goal of comparing the association of CPO with lipid droplets (LDs) and apoB48 in WT and 
E310Q CPO expressing Caco-2 cells. Differences in association would be considered in light of 
CPO activity (in WT) or lack thereof (in E310Q). 
 
a. Why E310Q?  
The selected mutation was on a key catalytic residue, E310. To assess any potential steric 
strain in the hCPO E310Q mutant, a 3-D model of the molecule was visualized using PyMOL 
(Fig. 14A). A close-up on the catalytic residue area revealed minimal change in structure due to 
the similarity of the two amino acids, glutamic acid (E) and glutamine (Q; Fig. 14B). Essentially, 
these two residues only differ in the terminal side chain, where E contains a -COOH group and Q 
has a -CONH2. Thus, modeling of the point mutation E310Q in hCPO verified that the steric 














Figure 14. The E310Q mutation substitutes a key catalytic residue in hCPO without contributing 
steric hindrance. A. Three-dimensional structure of hCPO in its monomeric form (PDB: 5RMV). 
E310, a key catalytic residue, is shown in magenta. Zinc cofactor is depicted as a yellow sphere. 
B. A close-up of the 3-D hCPO model showing a key catalytic residue E310 (top) and its mutated 
form Q310 (bottom). While the E310Q mutation does not add any steric hindrance, it effectively 
inhibits hCPO catalytic activity. 
 
b. Site-directed mutagenesis  
A PCR-based mutagenesis procedure was used to perform site-directed mutagenesis. 
Amplification of hCPO DNA using mutagenic primers was visualized via gel electrophoresis 
(Fig. 15). Bands of similar sizes were seen in +DMSO and -DMSO PCR products, indicating 






Figure 15. HCPO DNA was successfully amplified and resolved using gel electrophoresis. PCR 
products with and without DMSO exhibited similar bands.   
 
Prior to performing ethanol precipitation, the PCR products (± DMSO) were mixed with 
each other resulting in two products that contained about half of the +DMSO PCR reaction and 
half of the -DMSO. Both 50/50 products were digested by addition of 2.5% Dpn1. Ethanol 
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precipitation was performed only on one of the samples to purify it by concentrating the DNA 
and remove unwanted substances (Soares et al., 2012). Because of the complexity of the 
technique and the risk of losing DNA, it was decided that it would be appropriate to perform this 
only on one sample. Subsequent assessment of bacterial growth confirmed that the ethanol 
precipitation step was unnecessary, as colonies containing digested DNA were larger and more 
abundant than those containing ethanol purified DNA (n = 16 and n = 14, respectively).  
After transformation, plasmid from E.coli colonies was purified and visualized on a 1% 
agarose gel (Fig. 16A). DNA quantification showed that only colonies 2 and 3 had optimal 
amounts of plasmid required for sequencing.  
Sanger sequencing was used to confirm the presence of the novel mutation (C→G) in 
both samples. Presence of the E310Q mutation (*) was confirmed using sequence alignment 
against the hCPO WT (BLAST). The best mutant was selected on the basis of presence of the 












Figure 16. Confirmation of the mutagenesis in bacterial cells. A. After transformation, pcDNA 
from three E. coli colonies (1-3) was purified and visualized on a 1% agarose gel. B. Presence of 
the E310Q mutation (*) was confirmed using sequence alignment against the hCPO WT 
(BLAST). The missense mutation results in the coding of glutamine (Q) instead of glutamic acid 
(E). The best mutant was selected on the basis of presence of the mutation and overall DNA 
quality, as determined by the base calls in the chromatogram. In blue, reverse compliment of 
codon coding for E; in red, reverse compliment of codon coding for Q. 
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c. Testing the expression and catalytic activity of the hCPO E310Q mutant  
i. Western blotting 
To determine expression of the hCPO E310Q mutant, HEK293T cells were transiently 
transfected with pcDNA-hCPO E310Q. HEK293T cells were also transfected with empty vector 
pcDNA3.1(-) and pcDNA-hCPO WT, which were used as negative and positive controls, 
respectively. Each transfection was performed in duplicate. The cell extracts were subsequently 
collected and analyzed via western blotting. Analysis via western blotting revealed that the 
E310Q mutant had similar hCPO expression as the WT hCPO (Fig. 17A). 
ii. Carboxypeptidase Assay 
Two carboxypeptidase (CP) assays were run independently. Successful proteolytic 
cleavage of the substrate by CPO can be measured by a decrease in absorbance at 340 nm (Fig. 
17B). The average activity of the E310Q mutant (0.051 milliUnits/min) was significantly smaller 
than that of the WT (1.59 milliUnits/min) as determined by Student’s t-test (p < 0.005). In 











Figure 17. Analysis of hCPO E310Q expression and catalytic activity in mammalian cells. A. 
Extracts from HEK293T cells transiently transfected with empty vector (-), pcDNA-hCPO WT 
and pcDNA-hCPO E310Q were analyzed via western blotting. The E310Q mutant had similar 
hCPO expression as the WT. B. To measure enzymatic activity, HEK293T cell extracts were 
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incubated with 0.5mM Fa-EE substrate and their A340 was measured at 24°C every min for a 
total of 30 min. Values shown are averages from two separate carboxypeptidase (CP) assays.  
 
3.  Cell transfection and selection with hCPO WT and hCPO E310Q 
Caco-2 cells are considered a good model to study intestinal physiology, as they mimic 
molecular and physiological characteristics of the small intestinal epithelium (Natoli et al., 
2012). Although the Caco-2 cell line is an optimal choice for this study, its endogenous 
expression of CPO is low and thus insufficient to accurately assess enzyme activity (Fig. 10B,C). 
Therefore, to be able to study the activity of CPO in Caco-2 cells, it was necessary to produce a 
hCPO stably expressing cell line.  
 
a. Control experiments 
Prior to performing the transfection with pcDNA-hCPO WT and pcDNA-hCPO E310Q, 
several control and optimization experiments were conducted. First, to control for transfection 
efficiency, Caco-2 cells were transiently and stably transfected with a fluorescent plasmid. Also, 
the selection protocol was optimized by experimentally determining optimal G418 concentration. 
Finally, an attempt to optimize the transfection protocol included the testing of two transfection 
reagents, PEI and FuGENE6.  
 
i.  Determining effective G418 concentration 
In order to serve as a good selective agent, G148 must be used at an optimal 
concentration to induce cell lethality before cells reach confluency. Thus, G418 concentration as 
well as seeding cell density are key factors to consider when optimizing the selection protocol. 
Thus, an experiment was designed where Caco-2 cells were seeded at 43,000 cells/ml in a 6-well 
 40 
plate. G418 was added at three different concentrations: 0.6 mg/mL, 1mg/mL, and 4mg/mL. One 
well that received no G418 supplementation was used as a control. Medium was changed and 
supplemented with fresh G418 every 48 h. Cell toxicity was visually assessed at 48 h, 72 h, and 
92 h following the first G418 addition.  
Visual assessment of cell toxicity revealed that the minimum lethal concentration was 
between 0.6-1mg/mL. Approximately 48 h after the first G418 addition, cell toxicity was similar 
at 0.6 mg/mL and 1mg/mL of G418, whereas it was much more severe at 4 mg/mL, as seen by a 
considerably larger number of floating cells. At 92 h, the confluence at 1 mg/mL was half of that 
observed at 0.6 mg/mL. In contrast, the confluency at 4 mg/mL G418 was extremely low (10 %) 
with large cohorts of dead cells as compared to the control. These results suggest that a 
concentration of 4 mg/mL is not optimal, since large amounts of dead cells will correlate to 
secretion of undesired substances that may in turn affect the resistant cells leading to their death. 
Treatment with 0.6 mg/mL and 1 mg/mL G418 successfully killed non-resistant cells within 92 h 
without massive cell death. Thus, optimal lethal concentration required for optimal selection of 
resistant clones lies in the 0.6-1mg/mL range.   
 
ii. Transient transfection using fluorescent plasmids  
To assess the efficiency of transfecting Caco-2 cells using the PEI transfection reagent, 
Caco-2 cells were transiently transfected with various fluorescently tagged plasmids. Three 
plasmids with fluorescent tags were used for transfection: pEGFP-N2, pcDNA-GFP-CAAX, and 
pcDNA-mCherry-CAAX. The cells were observed under a fluorescent microscope 48 h post 
transfection. Quantification of transfection efficiency was calculated by dividing the number of 
fluorescent cells per field of view by that area (0.35 mm2) and multiplying by surface area of the 
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6-well plate (9.6 cm2). The total number of transfected cells was reported as the average of three 
fields of view. While all three transfections were successful, quantification of the observed 
fluorescence revealed varying transfection efficiencies (Fig. 18). The pEGFP-N2 had the highest 
transfection efficiency at ≅ 21,000/250,000 transfected cells per well, while pcDNA-mCherry-
CAAX had the lowest with ≅ 15,500/250,000. This suggests a transfection efficiency of 5-10% 
for this system.  
 
Figure 18. Caco-2 cells transiently transfected with fluorescently tagged plasmids. Plasmids 
pEGFP-N2 (A), pcDNA-GFP-CAAX (B), and pcDNA-mCherry-CAAX (C) were used as 
transfection markers to assess the transfection efficiency in Caco-2 cells. Fluorescent cells in 
three fields of view were manually counted and the average was used to estimate the transfection 
efficiency for each of the plasmids. Images show fluorescent cells, n = 8 in (A), n = 4 in (B), and 
n = 3 in (C). With a total cell number of about 250,000 cells per 9.6cm2 , 21,000 cells were 
transfected with pEGFP-N2 ,20,800 with pcDNA-GFP-CAAX, and 15,500 with pcDNA-mCherry-
CAAX.  
 
iii.  Stable transfection using a fluorescent plasmid  
Caco-2 cells were seeded in a 6-well plate at a density of 3 x105/mL and subsequently 
transfected with 3 μg total pEGFP-N2 pcDNA 24 h after (see Chapter 2, section 9). 48 h post-
transfection, the cells were subcultured at ≃ 54,500 cells/mL in 100 mm dishes with fresh 
medium. After selection with G418 (see above), cells were observed under a fluorescent 
microscope and three resistant clones presenting uniform, bright fluorescence were selected by 
marking their location on the plate. Two isolated resistant clones were grown to ≃70 % 
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confluency in a 24-well plate at 37°C and 5% CO2, and expanded into 60 mm dishes. 
Fluorescence was observed three weeks post-selection, suggesting that the transfection and 










Figure 19. Caco-2 cells stably transfected with a fluorescently tagged plasmid, pEGFP-N2. Here 
pictured are four fluorescent cells in a field of view. Two stably transfected clones were isolated 
and visualized with a fluorescent microscope to confirm fluorescence three weeks post-selection 
with G418.  
 
iv. Semi-transient transfection with pcDNA-hCPO WT and hCPO E310Q  
Caco-2 cells were transfected with 3 μg total pcDNA-hCPO WT and pcDNA-hCPO 
E310Q (see Chapter 2, section 9). 48 h post-transfection, the cells were subcultured at ≃ 10,600 
cells/mL for WT and 19,500 cells/mL for E310Q in 100 mm dishes. The cells were grown to 
confluency at 37°C and 5% CO2 for seven days, and media was changed every other day. After 
trypsinization and resuspension, a small volume of the cells was set aside to be counted. The 
remainder of the cells (2,012,800 cells WT and 3,180,800 cells E310Q) were harvested and lysed 
in lysis buffer (see Chapter 2, section 11). Cell extracts from transient hCPO WT and E310Q 
transfectants were analyzed via western botting with rabbit RP3-CPO as the primary antibody 
and HRP conjugated anti-Rabbit IgG as the secondary antibody (see Chapter 2, section 12). After 
a 55 min exposure, both transfectants exhibited bands at the expected product size for CPO 
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(about 42.5 kDa; Fig. 20). Nonetheless, the presence of a shadow in an empty lane adjacent to 










Figure 20. Caco-2 cells transiently transfected with pcDNA-hCPO WT and pcDNA-hCPO 
E310Q. Transient hCPO expression was assessed seven days post-transfection. Cell extracts of 
Caco-2 hCPO WT and E310Q transfectants were harvested, lysed, and analyzed via western 
blotting. Cell extracts from HEK293T cells transfected with pcDNA-hCPO WT were used as a 
positive control. 
 
v.   Optimization of transfection with PEI and FuGENE6  
Since the semi-transient transfection results did not confidently indicate a successful 
transfection, it was decided to revisit the transfection protocol to investigate the efficiency of the 
transfection reagent, PEI. Given that transfection efficiency is largely determined by the ratio of 
the transfection reagent to the DNA, I attempted to optimize the transfection protocol by testing 
the transfection efficiency using multiple PEI:DNA ratios. To do this, Caco-2 cells were seeded 
at 3x105 cells/well in 6-well plates and transfected with WT hCPO pcDNA at varying PEI:DNA 
ratios (μL PEI, and μg for DNA, respectively): 1:3, 3:3, 9:3, 15:3, 20:3, 1:1, 3:1, 9:1, 15:1, 20:1. 
Transfection with fluorescent plasmid pEGFP-N2 at a 9:3 ratio was used as a control.  
Cell extracts were harvested, lysed, and analyzed via western blotting (see Chapter 2, 
sections 11,12). None of the cell extracts showed expression (not shown). While these results 
may be suggestive of some form of human error in the experiment, the control sample showed 
abundant fluorescence, thus ruling out that possibility. An additional attempt to optimize the 
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transfection efficiency with CPO involved the use of a high efficiency transfection reagent, 
FuGENE 6. The transfection was done according to the manufacturer’s protocol (Roche) and 
pEGFP-N2 was used as a control. Assessment of the control sample post-transfection with 
FuGENE6 revealed minimal fluorescence, and it was concluded that this fluorescence was less 
than that observed in the previous optimization experiment with PEI. Thus, the low levels of 
fluorescence in the control sample suggested low transfection efficiency with FuGENE6. In 
contrast, high levels of fluorescence demonstrated that transfection with pEGFP-N2 using PEI 
was successful; however, low hCPO expression, possibly below the western blot detection limits, 
prevented confirmation of transfection. Thus, failure to detect hCPO expression via western 
blotting did not necessarily indicate failure of the transfection, but rather suggested low hCPO 
expression levels.  
 
b. Isolation of stable transfectants expressing hCPO WT and hCPO E310Q  
Caco-2 cells were seeded at 0.8 x105 cells/well in a 6-well plate and subsequently 
transfected with plasmids expressing hCPO WT, hCPO E310Q, and pcDNA3.1(-) empty vector 
(see Chapter 2, section 9). 48 h post-transfection, cells were passaged at 1:2 (vol/vol) and seeded 
into 100 mm dishes. Twelve hCPO WT resistant clones, thirteen hCPO E310Q, and nine empty 
vector resistant clones were grown in 24-well plates using the aforementioned protocol (see 
Chapter 2, section 10). Cell extracts were centrifuged at 5,000 g for 1 min and the pellet was 
resuspended in 1x sample buffer. Volumes of sample buffer added ranged from 100 to 300 μL 
and were directly proportional to the size of the pellet. Cell extracts from resistant clones (four 
hCPO WT, eight hCPO E310Q, and three empty vector) were analyzed by western blotting (see 
Chapter 2, section 12). Western blotting analysis of four hCPO WT and eight E310Q resistant 
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clones showed that all lacked CPO expression (not shown). A closer inspection of the western 
blotting results revealed that some resistant clones presented a single band of faint intensity at 
around 65 kDa, which corresponded to bovine serum albumin (BSA) protein.  
Resistant clones with BSA expression indicated protein presence in the sample, which 
argued for potential presence of hCPO. If hCPO expression was presumably too low to be 
detectable via western blotting, then further expanding the clones would increase the number of 
hCPO expressing cells thus allowing detection of expression. Thus, resistant clones with BSA 
expression (four hCPO WT and four hCPO E310Q) were transferred from their respective 6-well 
plates to 100 mm dishes for further expansion. After reaching 70-100% confluency, the resistant 
clones were harvested and lysed in lysis buffer (see Chapter 2, section 11). Eight resistant clones 
(four hCPO WT and four hCPO E310Q) showed no CPO expression, as determined by western 
blotting analysis (Fig. 21A) 
In a second attempt to isolate stably expressing hCPO WT and E310Q transfectants, 
Caco-2 cells were seeded at 3x105 cells/well in 6-well plate and transfected with WT, E310Q and 
3.1 pcDNA (see above). Resistant clones with healthy morphologies (nineteen hCPO WT, 
nineteen hCPO E310Q, and three empty vector) were harvested from the 100 mm dishes and 
expanded in 24-well plates. Twenty-one resistant clones (eleven hCPO WT and ten hCPO 























Figure 21. Resistant clones from stably expressing hCPO WT and hCPO E310Q transfectants 
showed no CPO expression. Caco-2 cells were transfected and subsequently selected with G418 
for three weeks. WT (n = 15) and E310Q (n = 14) resistant clones were harvested and analyzed 
via western blotting to test for hCPO expression. Extracts from HEK293T cells transfected with 
plasmids expressing hCPO, either WT (A,B) or L230K (A), and two empty vector clones Cl.3, 1 
(-) (B) were used as controls. 
 
4. Immunocytochemistry 
Previous research has shown an association between CPO and LDs in canine kidney cells 
and has further suggested the possibility of an association between CPO and chylomicrons. In 
this study, we investigated the association between CPO, LDs, and chylomicrons in Caco-2 cells, 
which are known to closely mimic intestinal physiology and anatomy. To test the potential 
association between CPO and LDs or chylomicrons, immunocytochemistry was performed using 
a culture of Caco-2 cells that contained pooled hCPO WT stable transfectants. Notably, the usage 
of a Caco-2 cell line that stably expressed both hCPO WT and E310Q would have been more 
optimal than a pooled culture containing a small number of hCPO WT expressing cells. 
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Nonetheless, transitioning to using this pooled culture was deemed as the next logical step after 
numerous unsuccessful attempts to create hCPO WT and E310Q stable transfectants.  
In order to compare any differences in association in differentiated and undifferentiated 
cells, a batch of Caco-2 cells from the pooled culture was differentiated. Caco-2 cells were 
differentiated into an epithelial monolayer of mature enterocytes by growing them in 6-well 
plates with coated coverslips (see Chapter 2, section 13) for 21 days. Prior to being analyzed via 
immunocytochemistry, undifferentiated and differentiated cells were fixed at 12 h and 48 h post-
feeding. For immunocytochemistry, the samples were divided into two groups: LD/CPO and 
apoB/CPO. Following permeabilization and blocking (see above), cells in the LD/CPO group 
were labeled with RP3-CPO primary antibody, whereas cells in the apoB/CPO group were 
labeled with both RP3-CPO and Apolipoprotein B primary antibodies. Similarly, secondary 
antibody anti-rabbit Alexa Fluor 555 was used for the LD/CPO and the same antibody in 
conjunction with anti-mouse Alexa Fluor 488 was used for the apoB/CPO group.  
Observation of the slides under the fluorescent microscope revealed that the number CPO 
expressing cells was low (not shown). This reduced number of transfected cells presented a 
challenge to assess association of CPO with LDs and chylomicrons. In addition, differentiated 
cells presented blurry staining, possibly as a result of the thickness of the cell monolayer (not 
shown). In light of these results, it was decided to transiently transfect the pooled culture of 
undifferentiated Caco-2 to increase the number of CPO expressing cells. Transiently transfected 
cells from the pooled Caco-2 cell culture were fixed at 6 h, 12 h, and 24 h post-feeding and 
analyzed via immunocytochemistry (Figs. 22,23). 
 Thirteen fields of view of each experimental condition were analyzed, with at least one 
hCPO transfected cell in each field of view (range 1-4, x̄: 1.6). LDs, apoB, and CPO puncta were 
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manually counted, and the association was computed by calculating how many of the total LD or 
apoB molecules were seen associated with CPO (expressed as % of total LDs or apoB). 
Similarly, association was computed in non-transfected cells to evaluate baseline background 
staining.  
CPO was associated with both LDs and apoB, with the highest % association found 12 h 
post-feeding (29.8% and 30.4%, respectively; Figs. 22A; 23A). Both LD and apoB presented the 
lowest association with CPO at 6 h (17.9% and 22.8%, respectively), reaching a maximum at 12 
h, and later slightly decreasing at 24 h (26.3% and 29.1%, respectively; Figs. 22B; 23B). CPO-
expressing cells exhibited defined, bright red puncta, which appeared as fuzzier and dimmer 
background spots in non-expressing cells. Non-transfected cells consistently exhibited lower 
association values, suggesting that the computed CPO, LD, and apoB puncta in transfected cells 
likely were not background staining (not shown). However, we note that the distribution of CPO 
and apoB puncta in Fig. 23A does not appear to correlate with the association values reported in 
Fig. 23B. Thus, we express a limited level of confidence regarding the apoB:CPO association 
reported herein.  
LD:CPO association was found to be significantly different at 6, 12, and 24 h (F = 4.27, p 
= 0.02), whereas apoB:CPO association was found to be non-significant between the time points 
















































Figure 22. CPO associated with lipid droplets in transiently transfected Caco-2 cells. A pooled 
culture of stable CPO transfectants was transiently transfected and fixed at 6, 12, and 24 h post 
feeding. A. The cells were immunostained with CPO antibody and BODIPY to observe lipid 
droplets. CPO-expressing cells exhibited defined, bright red puncta (A, cell on the left of  upper 
left panel), which appeared as fuzzier and dimmer background spots in non-expressing cells (A, 
cell on the right of  upper left panel). B. The LD:CPO association (%LDs) was determined using 
thirteen fields of view, and was found to be the highest at the 12 h mark. The LD:CPO 
































































Figure 23. CPO associated with apoB, a marker for chylomicrons, in transiently transfected 
Caco-2 cells. A pooled culture of stable CPO transfectants was transiently transfected and fixed 
at 6, 12, and 24 h post feeding. A. The cells were immunostained with CPO and apoB antibodies. 
B. The apoB:CPO association (%apoB) was determined using thirteen fields of view, and was 
found to be the highest at the 12 h mark. ApoB:CPO association did not significantly vary 



























1. Evaluation of expression data  
Protein expression data collected from several RNA-Seq and microarray databases (see 
Chapter 3) collectively identify the small intestine, more specifically the ileum epithelium, as the 
site of highest CPO expression in the human body. In this case, RNA-Seq and microarray data 
indicate the same site of maximum expression; however, these expression scores vary greatly 
from each other. More importantly, microarray data appears to show rather high levels of 
background expression. This becomes evident when comparing the expression scores for the 
anatomical structure with the lowest expression in the Affymetrix Human Genome U133 Plus 
2.0 Array microarray platform and the mRNASeq_HUMAN_GL-1 platform. As it would be 
expected, the lowest expression reported in the mRNASeq platform is 0, which corresponds to 
the spinal cord motor neuron. In contrast, the lowest mean score in the affymetrix microarray  
platform is 179, which corresponds to the myeloid progenitor cell. 
 For many years following the creation of the first Affymetrix GeneChip®  technology in 
1994, microarrays have continued to play an essential role in research (Lenoir and Giannella, 
2006). However, microarrays are being gradually replaced by newer, more complex sequencing 
technologies such as RNA-Seq. This transitioning to RNA-Seq can be understood in light of the 
numerous disadvantages associated with microarrays such as limited detection range, cross-
hybridization, and high background noise (Song et al., 2015; Wang et al., 2009; Zhao et al., 
2014). My findings show high levels of background noise in data collected from Bgee and 
Affymetrix Human Genome U133 Plus 2.0 Array platform. While it is important to identify 
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background noise, it may not drastically affect the interpretation of expression data with high 
expression levels. In contrast, interpretation of medium and low expression data can be easily 
affected by background noise, thus leading to an overestimation of expression. The present study 
found medium CPO expression in a myriad of anatomical entities such as the epididymal cauda 
and adrenal gland (Figs. 7D; 8B). In light of the large background noise (i.e. 231 in Affymetrix 
Human Genome U133 Plus 2.0), a corrected expression would place the aforementioned entities 
in the low expression range. This correction of the microarray expression data would then match 
the values of similar structures reported by RNA-Seq (Figs. 7A-C; 8A).  
 Additionally, analysis of CPO expression in IBD pathologies revealed several patterns 
that could provide insight into the physiological function of CPO. For example, Crohn's disease 
presents significant upregulation in colon tissue and downregulation in ileal tissue. Interestingly, 
the upregulation in colon tissue, reported to be upwards of 12-fold (p < 0.001; Fig. 12C), is the 
largest upregulation of CPO across all pathologies shown in the Genevestigator database (Peck et 
al., 2015). Preliminarily, this finding can raise questions regarding the underlaying mechanisms 
of Crohn's disease. Such mechanisms can presumably lead to overexpression of CPO in the 
colon, or alternatively, rely on a transport and subsequent relocation of CPO from ileal 
epithelium to the colon. Although it would be exciting to investigate these possibilities, low 
expression of CPO in the colon (1.5 pTPM in HPA, 1 pTPM in GTEx, and 0.4 pTPM in 
FANTOM 5; Fig. 7A-C, respectively) seems to undermine the relevance of such a large fold 
change.  
 The findings of Haberman et al. (2014) point to modulation of  CPO expression in the 
ileum with promising implications. The study, which included Crohn's disease patients aged 0-17 
(Satsangi et al., 2006) showed a significant downregulation of CPO in ileal tissue of (p < 0.001; 
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Fig. 12C). Since the ileum is the site of highest CPO expression (Figs. 7, 8), a downregulation of 
about 4-fold is considered prominent, and further suggestive of a function of CPO in this disease.  
 Crohn's disease is characterized by chronic intestinal inflammation emerging at an 
interface of genetic susceptibility, environmental factors, imbalance of enteric bacteria, and a 
strong immune response led by T-cells (Sartor, 2006; Shanahan, 2002). This pathology presents 
a variety of phenotypes, which have been classified into age (A1- 3), location (L1- 4) and 
behavior (B1- 3) categories according to the Montreal guidelines (Satsangi et al., 2006). Thia et 
al. (2010) investigated the clinical characteristics of 306 patients who had been diagnosed with 
Crohn's disease. They showed that 56% of diagnoses corresponded to patients aged 17 – 40 (A2), 
and only 11% corresponded to patients aged 0-16 (A1). Moreover, the study showed that the 
terminal ileum was the most commonly affected site, accounting for 45% of the total. While the 
disease may shift amongst behavior phenotypes (B1-3), it reportedly maintains a constant 
location (Baumgart and Sandborn, 2012). This would suggest that the findings of Haberman et 
al. (2014), although pertaining to a younger patient cohort, may likely apply to older patients as 
well. 
 Although a series of pathologies are expressed at varying levels across phenotypes 
(Antoni et al., 2014), a common feature in the pathogenesis of Crohn's disease is a defective 
intestinal mucosal barrier. The mucosal barrier represents the first line of immunological defense 
in the small intestine, so the emergence of disease associated perturbations directly affects 
intestinal function and integrity (Sartor, 2006). Such defects include, but are not restricted to, 
decreased presence of mucus biofilm, alterations in expression of intercellular junction proteins, 
increased transepithelial permeability linked to migration of leukocytes, and decreased 
production of antimicrobial peptides (Antoni et al., 2014; Baumgart and Sandborn, 2012). 
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Ultimately, these factors have been shown to produce epithelial apoptosis in Crohn's disease 
patients (Antoni et al., 2014; Zeissig et al., 2007). Thus, destruction of mucosal barrier 
epithelium, with appearance of gaps and microerosions (Antoni et al., 2014), would explain the 
downregulation of CPO in the ileal epithelium reported by Haberman et al. (2014). 
 Additionally, RNA-Seq data from Bgee showed high expression of CPO in Peyer’s 
patches (Fig. 7D), which are intimately associated with the immunological response of Crohn’s 
disease. These structures represent the first-line of adaptive immunological defense in the 
intestine (Kogan and von Andrian, 2008) and have significant presence in the ileum (Shah and 
Misra, 2011). In an effort to assess the presence of Peyer’s patches in the small intestine, a 
preliminary study by Cornes (1965) set out to quantify these organs across selected age groups 
ranging from gestational period to adolescence. The study showed that in adolescents, the 
number of patches ranged from 100 to 239, but most importantly, that the number and size of the 
patches increased with age (Cornes, 1965). Thus, an increased abundance of Peyer’s patches in 
later developmental stages could imply a similar pattern in CPO expression. Interestingly, RNA-
Seq data from Bgee shows highest expression in early adulthood (25 – 44 years old), and 
moderate expression in late adulthood, with no reports of earlier developmental stages. Taken 
together, these reports may indicate that Peyer’s patches and CPO expression could follow a 
bell-shaped curve; increasing from childhood until early adulthood, and subsequently decreasing 
after. A modulation of CPO expression resulting from variation in abundance of Peyer’s patches 
could suggest that CPO activity is relevant in these organs, possibly aiding in their proliferation. 
Another potential role of CPO in immunity is suggested by significant expression in basophils 
(Fig. 9). Although basophils are the least abundant granulocytes, they are known to play 
important roles in adaptive immunity, namely allergic reactions (Min et al., 2004). Future studies 
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should further investigate these promising associations to gain more insight into the 
physiological function of CPO.  
 
2. Evaluation of Caco-2 transfection attempts 
We set out to investigate the function of CPO in a stably-expressing Caco-2 cell model. 
Two separate attempts were made to stably transfect and isolate G418 resistant hCPO WT and 
E310Q clones; however, we found no CPO expression amongst the analyzed clones (n = 38; Fig. 
21). Analysis of CPO expression following a semi-transient transfection presumably showed 
expression in both hCPO WT and E310Q samples (Fig. 20). Nonetheless, this possibility was 
refuted after close inspection of the X-ray film, which showed a faint shadow on an empty lane, 
thus hinting at the possibility of spillover.  
These results prompted us to question if the inability to produce stable transfectants was 
related to CPO or rather cell-line specific. Lyons and Fricker (2011) reported creation of an 
epithelial Madin-Darby canine kidney (MDCK) cell line stably expressing CPO. MDCK cells 
can be easily transfected (Di et al., 2011) unlike Caco-2 cells, which are well-known for being 
difficult to transfect (Cerda et al., 2015). Other studies have successfully stably transfected Caco-
2 cells with a myriad of proteins including cyclooxygenase-2 (Tsujii et al., 1997), insulin-like 
growth factor I (IGF-I) receptors (Di Popolo et al., 2000), and integrin-initiated extracellular 
signal-regulated (ERK) kinase (Sanders and Basson, 2000). Notably, these studies used high-end 
transfection reagents (Lipofectamine and Lipofectamine PLUS), which contrasts with the cost-
effective reagent, namely PEI, used in this study. To our knowledge, we are the first study to 
report use of PEI to produce transiently and stably expressing Caco-2 cells. The reliability of the 
PEI reagent was demonstrated in separate transfection experiments with GFP (Figs. 18,19). 
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Given the abundant evidence showing that Caco-2 cells can be stably transfected, we 
wondered whether the inability to produce stable transfectants was CPO-specific. More 
specifically, we hypothesized that CPO overexpression in Caco-2 cells could be cytotoxic. Due 
to the low endogenous CPO presence in Caco-2 cells (Fig. 10), an increased expression post-
transfection could be toxic to the cells. Reeves et al. (2002) reported numerous cases of 
cytotoxicity linked to protein expression when attempting to create stably expressing cell lines. 
In this regard, Andréll and Tate (2013) argue against constitutive expression of membrane 
proteins when seeking to create stably expressing mammalian cell lines. Protein overexpression 
induces cellular stress, further leading to loss of expression over time and delayed cell growth. 
To address these issues, Andréll and Tate (2013) propose the use of an inducible system such as 
tetracycline, which enables inducible expression of the protein for short time periods. In our 
study, CPO was presumably constitutively expressed for 42-52 days, from time of transfection 
until harvesting of the cells. It is possible that CPO was expressed upon transfection and that 
factors such as extended length of the G418 selection (40-50 days), excessive stress and toxicity 
could have resulted in low protein expression at the time of analysis.  
 
3. CPO association with LDs and apoB in Caco-2 cells  
Using a culture with pooled stably expressing Caco-2 transfectants, we show that CPO 
associated with LDs and apoB; nonetheless, we acknowledge a discrepancy between the 
quantified apoB:CPO association, which ranges from 22-30%, and the association shown in the 
immunocytochemistry images (Fig. 23A), which appears lower. CPO association with LDs was 
found to be dependent on the time elapsed post-feeding, as seen by lowest association at 6 h 
(18%) and highest at 24 h (30%), followed by a small decrease at 48 h (26%) (p = 0.02; Fig. 
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22B). A similar, yet not statistically significant association pattern was shown by apoB (Fig. 
23B).  
The observed association between CPO and LDs expand on findings previously reported 
by Burke et al. (2018), which showed this association in differentiated MDCK cells. Burke et al. 
(2018) found an association that, similarly to ours, varied upon time elapsed from the last 
feeding until fixation; however, two notable differences were found when comparing association 
patterns. First, we report an increase in association from 6 h and 12 h time points (12%) which is 
6-fold higher than that reported by Burke et al. (2018). Secondly, the decrease in association 
from 12 h and 48 h time points (4%) represents a fourth of that reported in Burke et al. (2018). 
Despite use of similar methods by Burke et al. (2018), the variability between association levels 
could be due to differences in quantification techniques. Overall, the association of CPO with 
LDs confirms results previously reported by Burke et al. (2018) in a more optimal intestinal 
model, and further strengthens the hypothesis that CPO plays a role in lipid formation in 
enterocytes.  
We also report association of CPO with apoB in stably expressing undifferentiated Caco-
2 cells; nonetheless, we express a limited level of confidence in these results due to an apparent 
discrepancy between the immunocytochemistry images and the quantification data. Although not 
statistically significant, our results point to a similar pattern of association to that of LDs at 6 h, 
12 h, and 48 h time points (Fig. 23B). A rather weak fluorescence of apoB detected through 
immunocytochemistry (Fig. 23A) suggested lower abundance than initially expected. Thus, it 
appeared that low detection could correlate to low apoB secretion in undifferentiated Caco-2 
cells. Early work by Reisher et al. (1993) confirmed secretion of apoB in undifferentiated Caco-2 
cells, an event previously thought to occur only after differentiation. In a subsequent study, 
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Luchoomun et al. (1997) stably expressed the apoB48 isoform in Caco-2 cells and found that 
over 50% of the apoB48 was degraded intracellularly. 
 Since the present study sought to investigate the association between CPO and 
chylomicrons, we wondered if levels of apoB48, a well-known chylomicron biomarker 
(Nakajima et al., 2014), could predict the presence of chylomicrons in undifferentiated Caco-2 
cells. The findings of Luchoomun et al. (1997) indicate that undifferentiated Caco-2 cells can 
secrete chylomicron-like particles if subject to conditions that mimic a postprandial state, which 
can be achieved by supplementation of media with oleic acid. This evidence suggests that 
apoB48 metabolism, and to a lesser extent chylomicrons, can be studied in undifferentiated 
Caco-2 cells. Nonetheless, it appears that the use of differentiated Caco-2 cells may be more 
appropriate, as demonstrated by their use in a large amount of studies on chylomicron and 
apoB48 metabolism (Jiao et al., 1990; Nauli et al., 2014; van Greevenbroek et al., 1996).  
In addition, it is uncertain what percentage of the apoB detected in the 
immunocytochemistry assay pertained to apoB48 and/or apoB100, since the primary antibody 
appears to detect both isoforms of the apolipoprotein. Therefore, future studies should consider 
the use of western blotting analysis to resolve both apoB isoforms, or alternatively, the use of an 
apoB48-specific antibody. In addition, it is suggested to mimic postprandial state conditions in 
differentiated cells by use of oleic acid and/or lecithin to further enhance chylomicron production 
(Nauli et al., 2014). Overall, the evidence suggests that the conditions used in this study were not 





4. Conclusion  
In conclusion, the results of the present study show that CPO associates with LDs in 
undifferentiated Caco-2 cells and that this association is dependent on time elapsed post-feeding. 
Furthermore, this study used an intestinal model to expand on the findings of Burke et al. (2018), 
thus strengthening the hypothesis that CPO plays an intracellular role in the formation of lipid 
droplets in enterocytes. Future studies aiming to analyze intracellular CPO substrates and 
binding partners could provide insight into the potential physiological function of CPO. We also 
report that CPO associates with apoB in undifferentiated Caco-2 cells; however, we express a 
limited level of confidence in these results since the immunocytochemistry images presumably 
suggest lower association levels than those reported in the quantification data. Further, we 
acknowledge that the parameters used to study chylomicron metabolism were not optimal and 
hence should be revised ahead of future studies. Further work should investigate the association 
of CPO and chylomicrons in differentiated Caco-2 cells in the presence and absence of oleic 
acid. Lastly, a comprehensive analysis of CPO expression data revealed modulation of CPO 
expression in Crohn’s disease as well as expression in basophils and Peyer’s patches, all of 
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